These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 1640729)

  • 21. Natural killer cell regeneration after transplantation with mafosfamide purged autologous bone marrow.
    Almici C; Manoni L; Carlo-Stella C; Garau D; Cottafavi L; Rizzoli V
    Bone Marrow Transplant; 1995 Jul; 16(1):95-101. PubMed ID: 7581136
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Allogenic bone marrow transplantation versus autograft in acute lymphoblastic leukemia, in second remission in 113 children. Results of the Grupo Español de Transplante de Medula Niños (GETMON)].
    Badell I; Ortega JJ; Muñoz A; Bureo E; Madero L; Olivé T; Cubells J; Maldonado MS; Baro J; Díaz MA
    Sangre (Barc); 1996 Apr; 41(2):101-8. PubMed ID: 9045349
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of escalating doses of recombinant human interleukin-2 in correcting functional T-cell defects following autologous bone marrow transplantation for lymphomas and solid tumors.
    Bosly A; Guillaume T; Brice P; Humblet Y; Staquet P; Doyen C; Chatelain B; Franks CR; Gisselbrecht C; Symann M
    Exp Hematol; 1992 Sep; 20(8):962-8. PubMed ID: 1354620
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Immunotherapy with interleukin-2 and allogenic LAK cells in a patient with acute myeloblastic leukemia].
    Parrado A; Casares S; Carmona M; Campo T; Rodríguez Fernández JM
    Sangre (Barc); 1994 Oct; 39(5):393-6. PubMed ID: 7754446
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Repeated courses of high dose melphalan and unpurged autologous bone marrow transplantation in children with acute non-lymphoblastic leukemia in first complete remission.
    Michel G; Maraninchi D; Demeocq F; Perrimond H; Blaise D; Gaspard MH; Stoppa AM; Gastaut JA; Lepeu G; Novakovitch G
    Bone Marrow Transplant; 1988 Mar; 3(2):105-11. PubMed ID: 3048474
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transplantation of patients with high risk acute myeloid leukemia in first remission with autologous marrow cultured in interleukin-2 followed by interleukin-2 administration.
    Klingemann HG; Eaves CJ; Barnett MJ; Eaves AC; Hogge DE; Nantel SH; Reece E; Shepherd JD; Sutherland HJ; Phillips GL
    Bone Marrow Transplant; 1994 Sep; 14(3):389-96. PubMed ID: 7994260
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interleukin-2 +/- lymphocytes as consolidative immunotherapy after autologous bone marrow transplantation for hematologic malignancies.
    Fefer A; Benyunes M; Higuchi C; York A; Massumoto C; Lindgren C; Buckner CD; Thompson JA
    Acta Haematol; 1993; 89 Suppl 1():2-7. PubMed ID: 8475668
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Autologous bone marrow transplantation for acute myeloid leukaemia in children using total body irradiation and melphalan as conditioning regimen.
    Bonetti F; Montagna D; Porta F; Lanfranchi A; Zecca M; Comoli P; Personeni A; Gritti G; Maccario R; DeStefano P
    Leukemia; 1995 Apr; 9(4):570-5. PubMed ID: 7723386
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [IDA-FLAG (idarubicin, fludarabine, high dosage cytarabine and G-CSF)--an effective therapy regimen in treatment of recurrent acute myelocytic leukemia in children and adolescents. Initial results of a pilot study].
    Fleischhack G; Graf N; Hasan C; Ackermann M; Breu H; Zernikow B; Bode U
    Klin Padiatr; 1996; 208(4):229-35. PubMed ID: 8926688
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase I trial of humanized monoclonal antibody HuM195 (anti-CD33) with low-dose interleukin 2 in acute myelogenous leukemia.
    Kossman SE; Scheinberg DA; Jurcic JG; Jimenez J; Caron PC
    Clin Cancer Res; 1999 Oct; 5(10):2748-55. PubMed ID: 10537338
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activity of interleukin-2 in non-Hodgkin's lymphoma following transplantation of interleukin-2-activated autologous bone marrow or stem cells.
    van Besien K; Margolin K; Champlin R; Forman S
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S54-8. PubMed ID: 9457395
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High-dose systemic interleukin-2 therapy in stage IV neuroblastoma for one year after autologous bone marrow transplantation: pilot study.
    Pardo N; Martí F; Fraga G; Illa J; Badell I; Peiró M; Bertran E; García J; Rueda F; Cubells J
    Med Pediatr Oncol; 1996 Dec; 27(6):534-9. PubMed ID: 8888813
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A pilot study of interleukin-2 for adult patients with acute myelogenous leukemia in first complete remission.
    Cortes JE; Kantarjian HM; O'Brien S; Giles F; Keating MJ; Freireich EJ; Estey EH
    Cancer; 1999 Apr; 85(7):1506-13. PubMed ID: 10193940
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Induction by interleukin-7 of lymphokine-activated killer activity in lymphocytes from autologous and syngeneic marrow transplant recipients before and after systemic interleukin-2 therapy.
    Pavletic Z; Benyunes MC; Thompson JA; Lindgren CG; Massumoto C; Alderson MR; Buckner CD; Fefer A
    Exp Hematol; 1993 Sep; 21(10):1371-8. PubMed ID: 8359237
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The use of a sequential high dose recombinant interleukin 2 regimen after autologous bone marrow transplantation does not improve the disease free survival of patients with acute leukemia transplanted in first complete remission.
    Blaise D; Attal M; Pico JL; Reiffers J; Stoppa AM; Bellanger C; Molina L; Nedellec G; Vernant JP; Legros M; Gabus R; Huguet F; Brandely M; Hercend T; Olive D; Maraninchi D
    Leuk Lymphoma; 1997 May; 25(5-6):469-78. PubMed ID: 9250817
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Autologous bone marrow transfusion in the treatment of adults with hematologic neoplasms. Experiences from Bern].
    Brun del Re GP; Tschopp L; Cerny T; Bucher U
    Schweiz Med Wochenschr; 1989 Jun; 119(25):902-10. PubMed ID: 2667130
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunotherapy with interleukin 2 after ABMT in AML.
    Hamon MD; Prentice HG; Gottlieb DJ; Macdonald ID; Cunningham JM; Smith OP; Gilmore M; Gandhi L; Collis C
    Bone Marrow Transplant; 1993 May; 11(5):399-401. PubMed ID: 8504274
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recombinant human interleukin-3 (rH IL-3) in combination with remission induction chemotherapy in patients with relapsed acute myelogenous leukemia (AML): a phase I/II study.
    Wielenga JJ; Vellenga E; Groenewegen A; Sonneveld P; Löwenberg B
    Leukemia; 1996 Jan; 10(1):43-7. PubMed ID: 8558936
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study.
    Lemoli RM; Visani G; Leopardi G; Motta MR; Rizzi S; Testoni N; Curti A; Tura S
    Bone Marrow Transplant; 1999 Feb; 23(3):235-41. PubMed ID: 10084254
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High-dose melphalan with autologous hematopoietic stem cell transplantation for acute myeloid leukemia: results of a retrospective analysis of the Italian Pediatric Group for Bone Marrow Transplantation.
    Cesaro S; Meloni G; Messina C; Pillon M; Proglia A; Lanino E; Caniggia M; Bagnulo S; Pession A; Locatelli F;
    Bone Marrow Transplant; 2001 Jul; 28(2):131-6. PubMed ID: 11509930
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.